Longuespée, Rémi
Wefers, Annika K.
De Vita, Elena
Miller, Aubry K.
Reuss, David E.
Wick, Wolfgang
Herold-Mende, Christel
Kriegsmann, Mark
Schirmacher, Peter
von Deimling, Andreas
Pusch, Stefan http://orcid.org/0000-0002-3407-4249
Funding for this research was provided by:
Deutsche Krebshilfe (70112371)
Article History
Received: 20 February 2018
Accepted: 20 February 2018
First Online: 2 March 2018
Competing interests
: Stefan Pusch and Andreas von Deimling are patent holders of “Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)”, the enzymatic 2HG assay used for 2HG determination in this manuscript (WO2013127997A1).Andreas von Deimling is patent holder of “Methods for the diagnosis and the prognosis of a brain tumor”, the IDH1R132H specific antibody used in this manuscript (US 8367347 B2).Both patents are under the administrative supervision of the DKFZ technology transfer office.The rapifleX MALDI Tissuetyper was provided by Bruker Daltonik GmbH as part of a collaboration agreement between Bruker Daltonik GmbH, Proteopath GmbH, the Institute of Pathology- University of Heidelberg, and the Institute of Pathology-Technical University Munich.